Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
Rhea-AI Summary
Haemonetics (NYSE: HAE) will publish fourth quarter and fiscal year 2026 results at 6:00 am ET on May 7, 2026. A conference call with investors and analysts is scheduled for 8:00 am ET on May 7, 2026.
Participants can join via teleconference after registration to receive a dial-in number and personalized PIN. A live webcast will be available on Haemonetics' investor relations website and a replay will be accessible for one year starting May 7, 2026 at 11:00 am ET.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – HAE
On the day this news was published, HAE gained 1.05%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HAE was at $56.36, while peers showed mixed moves: INSP, ITGR, and LIVN were up, whereas ATEC and PRCT were down, suggesting stock-specific dynamics rather than a uniform sector rotation.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Earnings date set | Neutral | +1.3% | Announced Q3 FY26 results release timing and related conference call details. |
Prior earnings date scheduling news was followed by a modest positive move, suggesting such updates have historically been absorbed without major dislocations.
Recent news for Haemonetics centers on product approvals, portfolio reshaping, and regular earnings communications. On Jan 7, 2026, the company similarly announced the release timetable for third quarter fiscal 2026 results with a conference call and year-long replay. That announcement saw a 1.25% 24-hour move. Today’s fourth quarter and full-year 2026 earnings date notice fits this pattern of advance scheduling and standard investor-relations practice.
Historical Comparison
Past earnings date announcements saw an average move of 1.25%. Today’s Q4/FY26 scheduling update is similar in scope and structure.
Earnings communications progressed from setting the Q3 FY26 results date in January 2026 to now scheduling the Q4 and full fiscal year 2026 release, maintaining a consistent disclosure pattern.
Market Pulse Summary
This announcement sets the timetable for Haemonetics’ fourth quarter and fiscal year 2026 results, with publication at 6:00 am ET on May 7, 2026 and an 8:00 am ET conference call plus a 1 year replay. It continues a consistent pattern of advance earnings-date notices. Investors may focus next on the underlying financial performance, commentary on recent acquisitions, and any updates on capital allocation or leverage discussed during the call.
AI-generated analysis. Not financial advice.
The call can be accessed via teleconference at: Q4 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/7d678otf
A replay of the conference call and webcast will be available for one year beginning on May 7, 2026 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of
hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | ||
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations | |
(781) 356-9763 | (203) 733-4987 | |
Media Contact: | ||
Josh Gitelson, Sr. Director-Global Communications | ||
(781) 356-9776 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-fourth-quarter-and-fiscal-year-2026-results-may-7-2026-302731954.html
SOURCE Haemonetics Corporation